Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gamcemetinib by Bristol-Myers Squibb for Autoimmune Disorders: Likelihood of Approval
Gamcemetinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...
Data Insights
Gamcemetinib by Bristol-Myers Squibb for Inflammation: Likelihood of Approval
Gamcemetinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Inflammation. According to GlobalData, Phase I...